Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies

Digadoglucitol shows high diagnostic efficacy in preclinical models of neurological and oncological diseases. It delivers comparable effectiveness at half the dose and superior contrast enhancement at the full standard dose compared with established GBCAs. These preclinical findings suggest that digadoglucitol is a promising contrast agent to be considered for clinical translation, potentially allowing for reduced dosage while maintaining or improving diagnostic accuracy.